Supreme Court Won't Hear CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court rejected CareDx's appeal in its false-advertising clash with Natera, leaving a lower court ruling intact.
The U.S. Supreme Court has shut the door on CareDx, declining to take up the company's appeal in its ongoing false-advertising fight with genetic testing rival Natera. When the Supreme Court passes on a case like this, the lower court's decision stands — and that's a meaningful development for both companies and the investors watching them.
Natera, trading under the ticker NTRA, has been locked in a legal battle with CareDx over advertising claims tied to their competing transplant-monitoring tests. These aren't minor marketing squabbles — false-advertising disputes in the diagnostics space can directly impact market share, reimbursement positioning, and how physicians choose between competing products.
Read more Jobs Report, Home Prices, and Key Earnings to Watch This Week →
For traders, the Supreme Court's refusal to engage is essentially a green light for whatever outcome the lower court already handed down. CareDx has now exhausted a major avenue of appeal, which removes a layer of legal uncertainty that may have been hanging over Natera's stock. Less legal overhang typically means the market can price the fundamentals more cleanly.
Natera competes aggressively in transplant rejection surveillance and prenatal testing, markets where clinical credibility is everything. A false-advertising ruling that sticks at the appellate level reinforces that credibility. Watch how institutional positioning in NTRA shifts now that this particular legal wildcard is off the table — that's your tradeable signal here.
Continue reading at Yahoo Finance
